Erratum to “Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study” [EJC Skin Cancer 4 (2026) 100773]Eva Ellebaek, Dirk Schadendorf, Iva Gavrilova et al.|EJC Skin Cancer|2026Cited by 0